Company intelligence
Echosens
We are shaping the future of liver health. Because Liver Health Matters.
About Echosens
A pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is recognized worldwide as the reference for liver fibrosis and liver steatosis assessment with more than 6,270+ peer-reviewed publications and 250+ international guidelines recommendations. Echosens has made FibroScan® available in over 140+ countries enabling millions of liver examinations worldwide. We are working hand in hand with physicians, medical academic research, pharmaceutical companies for patient identification and monitoring in MASLD/MASH. As patient education is a major issue, we have created the "myliverexam" website that provides information about the role of the liver and why it is vital to the global health.
Verified activity
Signals from Echosens
4 published signals
Presence & Recognition
Echosens is attending the Interdisciplinary Obesity Days (IAT MUC) at the Rilano Hotel München in Munich from September 11 to 12, 2026.
Reported by Echosens
Research & Knowledge
Echosens published the updated Baveno VIII Consensus Guidelines (2026) reaffirming and expanding the role of FibroScan-based markers LSM and SSM by VCTE as cornerstones of non-invasive risk stratification in chronic liver disease.
Reported by Echosens
Presence & Recognition
Echosens is attending the 2026 edition of the ALEH Congress in Mexico City until tomorrow.
Reported by Echosens
Research & Knowledge
Echosens published a white paper by Dr. Radhika Vayani discussing the impact of FibroScan in-office liver assessments in primary care.
Reported by Echosens